Biosimilar breast cancer drug approved

Pink ribbon: Dr Dzulkefly (second from left) launching the Targeted Therapy Welfare Fund for Breast Cancer at Beacon Hospital. With him are (from left) Roche Malaysia general manager Lance Duan, Beacon Hospital medical director and consultant oncologist Datuk Dr Ibrahim Wahid and the hospital

PETALING JAYA: Good news for patients who cannot afford treatment for an aggressive type of breast cancer.

The Health Ministry has approved the biosimilar version of trastuzumab (a monoclonal antibody), a targeted therapy, for women with HER2-positive breast cancer, said minister Dr Dzulkefly Ahmad.